Lawsuit Alert: Investors who lost money with Mereo BioPharma Group plc (NASDAQ: MREO) should contact the Shareholders Foundation

An investor, who purchased shares of Mereo BioPharma Group plc (NASDAQ: MREO), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Mereo BioPharma Group plc connection with certain allegedly false and misleading statements.

Investors who purchased shares of Mereo BioPharma Group plc (NASDAQ: MREO) have certain options and for certain investors are short and strict deadlines running. Deadline: April 6, 2026. NASDAQ: MREO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

London based Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. Mereo BioPharma Group plc (NASDAQ: MREO) reported that its Net Loss increased from $29.46 million in 2023 to $43.25 million in 2024.

On December 29, 2025, Mereo BioPharma Group plc announced results from two Phase 3 studies for setrusumab, a treatment for conditions impacting bone metabolism. Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively. Both studies achieved their secondary endpoints of improvements in bone mineral density against comparators (placebo and bisphosphonates) with strong statistical significance. There was no change in the safety profile observed.

Shares of Mereo BioPharma Group plc (NASDAQ: MREO) declined from $5.02 per share on August 23, 2024, to as low as $0.20 per share on December 29, 2025.

The plaintiff claims that between June 5, 2023, and December 26, 2025, the Defendants misrepresented and/or failed to disclose that Mereo oversold setrusumab's efficacy by relying on earlier clinical data that did not support the statements being made about the subsequent clinical trials, that Mereo disregarded that neither of the subsequent trials would reach statistical significance against the primary endpoints of reducing fractures compared to the placebo, that the company failed to control for either the impacts of the standard of care nor of the placebo effect in the trials; (4) the methods of analyzing and predicting the trial results was based off of limited and incomplete data, and that as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Mereo BioPharma Group plc (NASDAQ: MREO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.